Mihalatos M, Danielides I, Belogianni J, Harokopos E, Papadopoulou E, Kalimanis G, Tsiava M, Triantafillidis J K, Kosmidis P A, Fountzilas G, Basdanis G, Agnantis N J, Yannoukakos D, Nasioulas G
Molecular Biology Research Center, HYGEIA-"Antonis Papayiannis", Athens, Greece
Cancer Genet Cytogenet. 2003 Feb;141(1):65-70. doi: 10.1016/s0165-4608(02)00723-9.
Familial adenomatous polyposis (FAP), a premalignant clinical entity inherited as an autosomal dominant trait, is characterized by the development thousands of adenomatous polyps of the colorectum during the 2nd and 3rd decade of life. Approximately 80% of patients with FAP harbor truncating germline mutations in the adenomatous polyposis coli (APC) tumor suppressor gene. We tested 24 members of six Greek families. All patients had the FAP phenotype, and one patient had an extracolonic tumor (medulloblastoma). Our method for testing was the polymerase chain reaction (PCR) amplification from genomic DNA extracted from whole blood, followed by automated DNA sequencing. Two novel truncating mutations (2601delGA and R923X) and three already-known mutations (R876X, Q1045X, and D1822V) were found. Other polymorphisms were also found. We identified the inactivating APC mutation in 12 of 13 of our FAP patients. Our results suggest that PCR sequencing is a reliable method for screening the APC gene for germline mutations.
家族性腺瘤性息肉病(FAP)是一种作为常染色体显性性状遗传的癌前临床病症,其特征是在生命的第二个和第三个十年期间在结肠直肠中形成数千个腺瘤性息肉。大约80%的FAP患者在腺瘤性息肉病大肠杆菌(APC)肿瘤抑制基因中存在截短的种系突变。我们对六个希腊家族的24名成员进行了检测。所有患者都有FAP表型,一名患者患有结肠外肿瘤(髓母细胞瘤)。我们的检测方法是从全血中提取的基因组DNA进行聚合酶链反应(PCR)扩增,随后进行自动DNA测序。发现了两个新的截短突变(2601delGA和R923X)和三个已知突变(R876X、Q1045X和D1822V)。还发现了其他多态性。我们在13名FAP患者中的12名中鉴定出了失活的APC突变。我们的结果表明,PCR测序是筛选APC基因种系突变的可靠方法。